Rovi/€ROVI

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Rovi

Laboratorios Farmaceuticos ROVI SA, ticker ROVI, is a Spain-based pharmaceutical company primarily engaged in developing, manufacturing, and commercializing pharmaceutical products. The company's activities span both domestic and international markets, focusing on a range of medical and drug treatments. Founded in 1946, ROVI continues to expand its reach and influence in the healthcare and pharmaceutical sectors.

Ticker

€ROVI

Primary listing

BME

Industry

Pharmaceuticals
Headquarters

Employees

2,197

ISIN

ES0157261019

Rovi Metrics

BasicAdvanced
€2.7B
19.23
€2.74
0.42
€0.76
1.44%

What the Analysts think about Rovi

Analyst ratings (Buy, Hold, Sell) for Rovi stock.

Bulls say / Bears say

Rovi's ambitious 2030 outlook projects operating revenue to reach between €1,146 million and €1,375 million, driven by significant growth in its Contract Development and Manufacturing Organization (CDMO) business, which is expected to contribute approximately €700 million by 2030. (Investing.com)
The company's specialty pharmaceutical segment showed strong performance in Q1 2025, with Okedi® (Risperidone ISM®) sales surging 133% year-over-year to €12.6 million, indicating successful commercialization and market acceptance. (Investing.com)
Rovi received a €36.3 million grant for research into prolonged-release investigational drugs and new aseptic filling technologies, which is expected to cover about 40% of the company's R&D investment needs over the next two fiscal years, supporting its innovation pipeline. (TradingView News)
Rovi warned that its 2024 EBITDA would be 10% to 15% lower than market consensus, primarily due to anticipated lower activity in its CDMO business during Q4, leading to a significant share price decline. (TradingView News)
The company reported a 20% decrease in net profit for 2024, attributed to an 8% decline in operating income, mainly due to reduced revenues from COVID-19 vaccine manufacturing, highlighting challenges in sustaining pandemic-related revenue streams. (CreditRiskMonitor)
Rovi's decision to retain its CDMO business, despite receiving non-binding offers, raises concerns about the company's ability to capitalize on potential strategic partnerships or divestitures that could unlock shareholder value. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Rovi Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Rovi Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €ROVI

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs